Cardiovascular disease models – Angiotensin II–induced Hypertension Mouse Model
Test efficacy of novel treatments against hypertension and hypertension-associated kidney injury using the Angiotensin II-Induced Hypertension Mouse Model
Angiotensin II-induced Hypertension Mouse Model Characteristics
Angiotensin II-induced hypertension mouse model is the most widely used translational model of progressive hypertensive cardiac remodeling, left ventricular dysfunction and cardiac fibrosis induced by chronic Angiotensin II (AngII) infusion. Chronic infusion of AngII, an endocrine hormone within the renin-angiotensin-aldosterone system (RAS), promotes vasoconstriction, cellular proliferation, hypertrophy, and fibrosis, leading to sustained hypertension, cardiac hypertrophy, and ultimately results in heart failure.
The chronic hypertension mouse model closely mirrors human hypertensive heart disease, making it a highly translationally relevant research model for testing interventions aimed at reducing hypertension-driven cardiac remodeling and hypertension-induced heart failure. Due to the effects of AngII infusion on systemic blood pressure, this model is also suitable for studying hypertension-induced kidney injury and evaluating therapies for renal complications associated with chronic hypertension.
✓ The model is relevant for hypertension-induced cardiovascular dysfunction and related heart failure, as well as kidney injury.

Take advantage of InnoSer’s combined expertise in cardiovascular diseases and in-house nephrology capabilities to obtain robust efficacy data of your compound in managing hypertension-associated cardiac failure and kidney disease. Contact us today to discuss how this model can support your research objectives in hypertension, cardiac fibrosis, hypertension-induced kidney injury, and heart failure.
Angiotensin II–induced Hypertension Mouse Model Sample Data

The Angiotensin II-induced hypertension mouse model is relevant for efficacy studies aimed at improving cardiac dysfunction and associated heart failure in hypertensive conditions.
In the Ang II mouse model, the heart-weight/body-weight ratio is used to quantify cardiac hypertrophy.
Angiotensin II–induced Hypertension Mouse Model Readouts
The People Behind Your Research
Yanick Fanton, PhD, Chief Scientific Officer
As Chief Science Officer at InnoSer, Yanick is responsible for all customer studies at InnoSer and takes care of the scientific and technical coordination.
Discover Other Related Cardiovascular Disease Mouse Models
Stay Curious: More Articles to Explore
AAALAC Accreditation
InnoSer has earned the AAALAC accreditation, demonstrating our commitment to responsible animal care and use. AAALAC International is a nonprofit organization that promotes the humane treatment of animals in science through voluntary accreditation and assessment programs. Our accreditation is valid for three years, incl. 2023. Read more about the AAALAC accreditation programme here.
Animal Welfare
The 3Rs impact everything from policy and regulatory change to the development and uptake of new technologies and approaches. This is why InnoSer has ongoing commitment and monitoring of these processes. The steps we practice maximize our ability to replace, reduce and refine animal involvement and facilitate our commitment to these principles when it comes to research and drug development.
info@innoserlaboratories.com